লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

bouchara-recordati - kalcio karbonatas/kolekalciferolis/sorbitolis - tabletės - 1250 mg/400 tv/0,336 mg - calcium, combinations with vitamin d and

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - retinolis/kolekalciferolis/askorbo rūgštis/tiaminas/riboflavinas/piridoksinas/cianokobalaminas/nikotinamidas/kalcio pantotenatas/folio rūgštis hidratas/kalcis/fosforas - dengtos tabletės - 900 tv/100 tv/50 mg/1 mg/1 mg/0,6 mg/1 µg/5 mg/2 mg/5 ml; 600 tv/80 tv/10 mg/0,25 mg/0,3 mg/0,3 mg/0,2 µg/3 mg/1,2 mg/0,04 mg/12,5 mg/10 mg; 900 tv/100 tv/50 mg/1 mg/1 mg/0,6 mg/1 µg/5 m - multivitamins and calcium

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - retinolis/kolekalciferolis/askorbo rūgštis/nikotinamidas/kalcio pantotenatas/riboflavinas/piridoksinas/tiaminas/folio rūgštis hidratas/cianokobalaminas/kalcis/fosforas - dengtos tabletės - 600 tv/80 tv/10 mg/3 mg/1,2 mg/0,3 mg/0,3 mg/0,25 mg/0,04 mg/0,2 µg/12,5 mg/10 mg - multivitamins and calcium

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - retinolis/kolekalciferolis/askorbo rūgštis/nikotinamidas/tokoferolio acetatas/kalcio pantotenatas/piridoksinas/riboflavinas/tiaminas/folio rūgštis hidratas/cianokobalaminas - dengtos tabletės - 2,94 mg/0,4 mg/60 mg/20 mg/15 mg/10 mg/2 mg/1,7 mg/1,5 mg/0,4 mg/6 µg - multivitamins, plain

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - vitaminas a/kolekalciferolis/askorbo rūgštis/tiaminas/riboflavinas/piridoksinas/cianokobalaminas/nikotinamidas/folio rūgštis/kalcio pantotenatas/visų racematų alfa-tokoferilio acetatas+kalcis/fosforas/geležis/varis/cinkas/magnis/manganas/molibdenas - dengtos tabletės - 5000 tv/200 tv/60 mg/1 mg/1,2 mg/2 mg/3 µg/13 mg/0,4 mg/5 mg/10 mg + 15 mg/12 mg/10 mg/1 mg/3 mg/20 mg/1 mg/0,1 mg - multivitamins and other minerals, incl. combinations

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizminis - selektyvūs imunosupresantai - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

novartis europharm limited  - alpelisib - krūties navikai - antinavikiniai vaistai - piqray yra nurodytas kartu su fulvestranto gydyti moterims po menopauzės, ir vyrų, su hormonų receptorių (hr)-teigiamas žmogaus epidermio augimo faktoriaus receptorių 2 (her2)-neigiama, lokaliai išplitusio arba metastazavusio krūties vėžio su pik3ca mutacijos, po ligos progresavimo po endokrininės terapijos monotherapy (žr. skyrių 5.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidaklopridas, ožkos - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). veterinarinis vaistas gali būti naudojamas kaip blusų alerginio dermatito (fad) gydymo strategijos dalis..  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). veterinarinis vaistas gali būti naudojamas kaip blusų alerginio dermatito (fad) gydymo strategijos dalis..

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidų vaizdavimas - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatos navikai, kastracija-atsparus - terapiniai radiofarmaciniai preparatai - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.